Advent Weighs Options Including $1.5 Billion BioDuro Sale
- Buyout firm also mulling China IPO for contract drug company
- Advent in talks with potential financial advisers on options
This article is for subscribers only.
Buyout firm Advent International is considering options for its health-care company BioDuro-Sundia including a sale that could give the asset a value of at least $1.5 billion, according to people familiar with the matter.
Other options being evaluated with financial advisers include an initial public offering in China, the people said, asking not to be identified because the matter is confidential. Private equity firms and industry players could be interested in acquiring the drug research, development and manufacturing business, they said. A sale could even value BioDuro-Sundia at more than $2 billion, two of the people said.